<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03998215</url>
  </required_header>
  <id_info>
    <org_study_id>Dembinski2012</org_study_id>
    <nct_id>NCT03998215</nct_id>
  </id_info>
  <brief_title>Diphtheria Vaccination in Adolescents With Inflammatory Bowel Disease</brief_title>
  <official_title>Immunogenicity of Diphtheria Booster Vaccination in Adolescents With Inflammatory Bowel Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Warsaw</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wroclaw Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Poznan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Silesia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Warsaw</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of the immunogenicity and safety of booster immunization against diphtheria in
      children with inflammatory bowel disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2012</start_date>
  <completion_date type="Actual">January 1, 2015</completion_date>
  <primary_completion_date type="Actual">January 1, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Achieving seroprotective antibody concentration</measure>
    <time_frame>after 4-8 weeks</time_frame>
    <description>Antibody concentrations ≥0.1 IU/ml indicated protection against diphtheria, while levels ≥1.0 IU/ml were considered to ensure long-term protection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Booster response</measure>
    <time_frame>after 4-8 weeks</time_frame>
    <description>Booster response was defined as a post-vaccination antibody concentration ≥0.4 IU/mL in initially seronegative subjects or as a fourfold increase of antibody concentration in initially seropositive ones.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>3 days</time_frame>
    <description>Evaluation of adverse effects after vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory bowel disease exacerbation occurrence.</measure>
    <time_frame>after 4-8 weeks</time_frame>
    <description>Disease exacerbation assessed according to the Paediatric Ulcerative Colitis Activity Index (PUCAI) for patients with ulcerative colitis or Pediatric Crohn's Disease Activity Index (PCDAI) for patients with Crohn's disease.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Diphtheria</condition>
  <condition>Inflammatory Bowel Diseases</condition>
  <arm_group>
    <arm_group_label>Diphtheria booster vaccination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One booster dose of the trivalent vaccine against diphtheria, tetanus and acellular pertussis</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Diphtheria booster vaccination</intervention_name>
    <description>Participants received intramuscularly in the deltoid muscle one dose of the trivalent vaccine against diphtheria, tetanus and acellular pertussis</description>
    <arm_group_label>Diphtheria booster vaccination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of Crohn's disease or ulcerative colitis based on standard clinical,
             endoscopic, histologic and radiographic criteria (Porto criteria),

          -  vaccination, as a part of the basic vaccination course, with five doses of diphtheria,
             tetanus and whole-cell pertussis vaccine, without booster dose after the age of 6,

          -  written consent of the patient's legal guardians and the patient himself if he/she
             turns 16 years of age.

        Exclusion Criteria:

          -  serious exacerbation of inflammatory bowel disease defined as Paediatric Ulcerative
             Colitis Activity Index (PUCAI) &gt; 65 points for patients with ulcerative colitis or
             Pediatric Crohn's Disease Activity Index (PCDAI) &gt; 40 points for patients with Crohn's
             disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aleksandra Banaszkiewicz, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Medical University of Warsaw</affiliation>
  </overall_official>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 21, 2019</study_first_submitted>
  <study_first_submitted_qc>June 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2019</study_first_posted>
  <last_update_submitted>June 21, 2019</last_update_submitted>
  <last_update_submitted_qc>June 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Warsaw</investigator_affiliation>
    <investigator_full_name>Lukasz Dembinski</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

